The INHBE Knockout SK-OV-3 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-OV-3 human ovarian adenocarcinoma cell line, in which the INHBE gene has been disrupted to ablate inhibin beta E expression. This loss-of-function model is designed for investigations into the role of inhibin beta E within TGF-beta superfamily signaling networks in an epithelial ovarian cancer context, providing a genetically defined tool for functional genomics and drug target validation studies.
SK-OV-3 is an epithelial-like cell line originally established from the ascites fluid of a patient with ovarian adenocarcinoma. It is extensively employed as a model for ovarian cancer research, particularly for examining signal transduction pathways, tumor cell proliferation, apoptosis, migration, and therapeutic responses. The cell line??s robust expression of key TGF-beta and activin pathway components makes it a suitable host for interrogating INHBE function.
INHBE encodes inhibin beta E, a TGF-beta superfamily member that heterodimerizes with INHA to form inhibin E. This ligand antagonizes activin signaling by competing for activin type II receptors (ACVR2A) and, with betaglycan, sequestering type I receptors such as ACVR1B. Under basal conditions, inhibin E suppresses activin-driven phosphorylation of SMAD2 and SMAD3, thereby attenuating SMAD4-dependent transcriptional responses. Disruption of INHBE removes this negative regulation, leading to enhanced activin A-mediated signaling through TGFBR1/TGFBR2?CSMAD2/3?CSMAD4 cascades and altered expression of downstream genes controlling proliferation and apoptosis.
In the SK-OV-3 ovarian cancer background, disruption of INHBE is expected to shift the balance of TGF-beta superfamily signaling, as ovarian tumor cells frequently exhibit dysregulated activin/inhibin pathways. The resulting enhancement of SMAD-mediated transcription may influence key malignant phenotypes, including proliferation, apoptosis resistance, and invasive capacity. This polyclonal knockout population therefore provides a physiologically relevant platform to dissect the contribution of inhibin E to ovarian cancer cell behavior and to evaluate the therapeutic potential of modulating this pathway.
Researchers can use these cells in western blotting and RT-qPCR to confirm pathway modulation, RNA-seq for transcriptome profiling, flow cytometry for cell cycle and apoptosis assessment, and functional assays for proliferation, apoptosis, migration, and invasion. SMAD reporter assays directly monitor pathway activity. This model supports ovarian cancer research, TGF-beta superfamily signaling studies, functional genomics, and drug target validation. For additional technical details, please contact Ascent Research.
